Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The global anti-obesity drug industry is set to experience strong growth, owing to rising prevalence of obesity, escalating health and wellness awareness, growing popularity of combination therapies, and advancements in new drug formulations

  80% confidence

• The Global Anti-Obesity Drug Market is estimated to be valued at USD 25.87 Bn in 2025 and is expected to reach USD 82.55 Bn by 2032

  80% confidence

• High cost of treatment and growing competition from non-pharmacological approaches might slow down market growth to some extent during the forecast period

  80% confidence

• Prescription drugs segment is slated to dominate the industry, accounting for nearly two-thirds of the global anti-obesity drug market share by 2025

  80% confidence

• More than 1 billion people will be living with obesity by 2030

  80% confidence

• GLP-1 receptor agonists like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are revolutionizing obesity treatment

  80% confidence

• North America is expected to retain its dominance, capturing 38.3% of the global market share in 2025

  80% confidence

• GLP-1 receptor agonists segment is expected to account for a market share of 22.1% in 2025

  80% confidence

• Asia Pacific, with an estimated share of 24.2% in 2025, is anticipated to emerge as a highly lucrative market for anti-obesity drug companies

  80% confidence

• The market will exhibit a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032

  80% confidence